NVIC Articles

History-of-RSV-vaccine-in-America

Disease-Vaccine-Landing-Page/Respiratory-Syncytial-Virus-(RSV)/History-of-RSV-vaccine-in-America

Latest articles

Browse Articles

Placeholder image
Page

On July 17, 2023 the FDA approved the drug nirsevimab under the trade name Beyfortus, a monoclonal antibody, for the prevention of RSV. Though the CDC has determined that it...

Placeholder image
Page

On May 31, 2024, the FDA approved MRESVIA, an mRNA RSV vaccine manufactured by Moderna, for use in persons 60 years of age and older. The approval of MRESVIA was...

Placeholder image
Page

In August 2022, Pfizer issued a press release announcing the success of their Phase 3 clinical trial of a bivalent RSV prefusion F vaccine candidate, RSVpreF, in persons 60 years...

Placeholder image
Page

In October 2022, GlaxoSmithKline (GSK) pharmaceutical issued a press release that reported their RSV vaccine reduced severe RSV illness by 94.1 percent in persons 60 years and older. GSK also...

Topics
Select disease / vaccine